NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones
- Patient enrollment has been completed for the STRO-002 Phase 1 ovarian cancer dose-expansion cohort, and an interim data update is expected in the second half of 2021 – - STRO-001 Phase 1 dose escalation for non-Hodgkin’s lymphoma and multiple myeloma is ongoing to...
Sutro Biopharma to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China
SOUTH SAN FRANCISCO and SHANGHAI, China, Oct. 12, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck
SOUTH SAN FRANCISCO, Sept. 30, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...
Sutro Biopharma Announces Expansion of Leadership Team
- Nicole M. Chieffo, MBA, appointed to Vice President of Clinical Operations - Werner Rubas, Ph.D., appointed to Vice President of Preclinical Development SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug...
2021 Wells Fargo Virtual Healthcare Conference – Presentation
Webcast, Sept 9, 2021 at 3:20pm EST
Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
SOUTH SAN FRANCISCO, August 18, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
12th Annual Wedbush PacGrow Healthcare Virtual Conference 2021 – Presentation
Webcast, Aug 11, 2021 at 11:20am PST Download Presentation, Click Here